Table 3. Percentage of injected mosquitoes displaying eGFP expression in body tissues after coinjection of ONNV-eGFP and dsnsP3 or dsAgAgo2 at 3 and 6 dpi.
| 3 dpi
|
6 dpi
|
|||||
|---|---|---|---|---|---|---|
| Treatment | Head | Thorax | Abdomen | Head | Thorax | Abdomen |
| ONNV-eGFP + no dsRNA | 10% (4/40) | 85% (34/40) | 0% (0/40) | 36% (14/44) | 93% (41/44) | 20% (9/44) |
| ONNV-eGFP + dsβgal | 34% (20/58) | 86% (50/58) | 34% (20/58) | 57% (30/53) | 89% (47/53) | 57% (30/53) |
| ONNV-eGFP + dsnsP3 | 23% (12/52) | 38% (20/52) | 0% (0/52) | 36% (20/55) | 71% (39/55) | 16% (9/55) |
| ONNV-eGFP + dsAgAgo2 | 98% (62/63) | 100% (63/63) | 97% (61/63) | 100% (36/36) | 100% (36/36) | 100% (36/36) |